Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases

Interventions

BIOLOGICAL

sargramostim

DRUG

bexarotene

GENETIC

cytogenetic analysis

GENETIC

fluorescence in situ hybridization

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

PROCEDURE

biopsy

Trial Locations (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00425477 - Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter